Prostate cancer, Secondary cancers
Open
Phase 1/2
This trial is looking at a drug called pembrolizumab in combination with other drugs in prostate cancer.
It is for people with metastatic castration resistant prostate cancer (mCRPC). This means that the cancer:
has spread to other parts of the body (advanced prostate cancer)
got worse despite having hormone treatment
Recruitment start: 1 February 2017
Recruitment end: 22 October 2027
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Johann DeBono
Merck Sharp & Dohme LLC
Last reviewed: 15 Jun 2025
CRUK internal database number: 17603
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
